BioNTech、辉瑞大举进攻,PD-(L)1/VEGF双抗开始分化了

氨基观察
Jan 11

文|氨基观察1月6日,美国Instil Bio宣布,其子公司Axion Bio决定终止与宜明昂科此前达成的合作协议,涉及PD-L1/VEGF双抗AXN-2510以及CTLA-4单抗AXN-27M。站在Instil Bio角度来看,这样的抉择也不难理解。AXN-2510原本是其陷入困境后,抓住的救命稻草,其也曾受益于PD-1/VEGF双抗领域的进展,股价一度从12美元冲击至92美元,只是不曾设想,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10